299 related articles for article (PubMed ID: 12820439)
1. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
3. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
4. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
7. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
Welsh SJ; Bellamy WT; Briehl MM; Powis G
Cancer Res; 2002 Sep; 62(17):5089-95. PubMed ID: 12208766
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells.
Horiuchi A; Imai T; Shimizu M; Oka K; Wang C; Nikaido T; Konishi I
Anticancer Res; 2002; 22(5):2697-702. PubMed ID: 12529984
[TBL] [Abstract][Full Text] [Related]
9. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
Sivridis E; Giatromanolaki A; Gatter KC; Harris AL; Koukourakis MI;
Cancer; 2002 Sep; 95(5):1055-63. PubMed ID: 12209691
[TBL] [Abstract][Full Text] [Related]
10. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis.
Giatromanolaki A; Sivridis E; Maltezos E; Athanassou N; Papazoglou D; Gatter KC; Harris AL; Koukourakis MI
Arthritis Res Ther; 2003; 5(4):R193-201. PubMed ID: 12823854
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
[TBL] [Abstract][Full Text] [Related]
12. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
13. A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.
Kurebayashi J; Otsuki T; Kurosumi M; Soga S; Akinaga S; Sonoo H
Jpn J Cancer Res; 2001 Dec; 92(12):1342-51. PubMed ID: 11749701
[TBL] [Abstract][Full Text] [Related]
14. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma.
Valković T; Dobrila F; Melato M; Sasso F; Rizzardi C; Jonjić N
Virchows Arch; 2002 Jun; 440(6):583-8. PubMed ID: 12070596
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
16. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Ortholan C; Durivault J; Hannoun-Levi JM; Guyot M; Bourcier C; Ambrosetti D; Safe S; Pagès G
Eur J Cancer; 2010 Nov; 46(16):3022-36. PubMed ID: 20729074
[TBL] [Abstract][Full Text] [Related]
18. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
